To complement our news releases, here are additional news tips reported by the American Heart Association's Public and Media Relations from more than 3,600 abstracts. Note: Stories are embargoed until papers are presented or poster sessions begin. Times are indicated with each entry; however, all embargoes will lift by 4 p.m. CST each day. For more information Nov. 7 10, call Carole Bullock, Bridgette McNeill, or Julie Del Barto (broadcast) at the Ernest N. Morial Convention Center, New Orleans: (504) 670-6500. Before or after these dates, call Public and Media Relations in Dallas: (214) 706-1173 or 706-1396.
8:30 a.m. Abstract 2666 Testosterone boosts blood flow to heart muscle in men with CAD. British doctors report positive results from experimental testosterone supplementation in men with coronary artery disease (CAD). Twenty-two men (average age 57) with known CAD were randomized to take 80 milligrams of testosterone daily or placebo. After eight weeks their treatment was reversed. After each eight weeks the men rested and underwent cardiovascular magnetic resonance (CMR) scans. Computer analyses of CMR images calculated blood supply to the two membranes around the heart muscle, the myocardium. Both of these "myocardial perfusion reserve indices" showed significant improvement on testosterone treatment. "In men with CAD and low plasma testosterone, chronic oral testosterone treatment improves myocardial perfusion reserve," the authors reported. Researchers said their findings support the potential clinical use of the male hormone to treat men with CAD.
8:30 a.m. Abstract 3721 Cardiovascular risk factor trends: there's good news and not-so-good news. Researchers taking a fresh look at behavioral factors affecting cardiovascular disease risk find one trend that's good, and another that's decidedly not. A comparison of data from two large national health surveys (NHANES 1999-2000 and NHANES III) shows that s
Contact: Carole Bullock
American Heart Association